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ABSTRACT 
Background and Objectives: cancer cases are gradually increasing, and most treatments 
still cause several adverse reactions, such as myelosuppression. When neutrophils 
decline, febrile neutropenia (FN) can be triggered, considered an oncological emergency, 
leaving patients susceptible to infections. Therefore, it is necessary to determine the best 
treatment, seeking to reduce the risk of complications. The purpose of this review is to 
identify, in literature, randomized clinical studies that compare different treatments for 
FN in pediatric onco-hematological patients. Content: a systematic search was carried 
out on the PubMed database, for randomized clinical studies, from 2009 to 2019, in 
English, using “Febrile Neutropenia”, “Pediatric”, and “Therapeutics” as descriptors. A 
total of 233 articles were found, seven of which were selected for review. The most 
described antimicrobial for FN treatment was Piperacillin/Tazobactam (PIP/TAZ) and its 
use is justified by its spectrum of action to cover the most frequent microorganisms in 
patients with FN. The possibility of using oral antimicrobials may be an alternative and 
should be analyzed. The description of the risk classification criteria is essential to guide 
the therapy, and new tools, such as the stewardship, add safety to patient care. 
Conclusion: the most used antimicrobial to treat FN was PIP/TAZ, and the establishment 
of standardized risk classification scores in pediatric onco-hematological patients is 
essential to guide clinical management in FN treatment. 









 It is estimated that 420 thousand new cases of cancer will occur in Brazil for the 
2018-2019 biennium, excluding non-melanoma skin cancer from this number. 
Considering that the median percentage of childhood and juvenile tumors observed is 3%, 
it is expected that 12,500 new cases of cancer will occur in children and adolescents (up 
to 19 years old). The Southeast and Northeast regions are those with the highest numbers, 
5,300 and 2,900, respectively, followed by the Center-West (1,800), South (1,300) and 
North (1,200)1. 
 Despite advances in cancer treatment, the main drugs used to treat neoplasms, 
hematology and solid tumors still cause numerous adverse reactions. One of the main 
ones that competes at great risk to patients is myelosuppression, characterized by a 
decrease in the elements of the immune system, leaving patients exposed to various 
infections. When there is a decline in neutrophils, the first line of defense against some 
pathogens, it can trigger febrile neutropenia (FN), considered an oncological emergency.2 
 The severity of FN can vary due to the type and cycle of therapy, type of cancer, 
sex and clinical conditions of patients. The incidence of FN in the United States is 
estimated at 60,294 cases per year, 7.83 cases per 1,000 cancer patients, and 43.3 cases 
per 1,000 hematological tumor patients. The epidemiology of FN is related to some 
factors, which may be responsible for 50% of deaths in patients receiving chemotherapy 
for solid tumors and 75% for leukemias. In relation to Brazil, there are no general data; 
however, we can use as a basis the results of a study carried out in a hospital in 
northeastern Brazil with onco-hematological children and adolescents, which out of 180 
occurrences, 87 were FN, giving rise to the 74 cases of infection reported in the study.2-4 
 According to the guideline published by the European Society for Medical 
Oncology (ESMO) in 2016, FN is defined as oral temperature ˃ 38.3ºC or two 
consecutive measurements ˃ 38.0ºC for 2h and absolute neutrophil count (ANC) of 500 
cells/mm³, or an expectation that it will decrease to below 500 cells/mm³. 5 When FN is 
detected, the rapid onset of broad-spectrum empirical antibiotics is necessary, as the 
permanence of patients with FN can lead to delay in treatment, which directly or indirectly 
affects morbidity and mortality.6  
 Cancer patients have a higher risk of infection, not only due to chemotherapy 
treatment that induces immunosuppression and neutropenia, but also due to 
hypogammaglobulinemia and loss of normal physiological barriers. This increases the 
 
 
risk of infections by bacteria, viruses, fungi and parasites, as well as complications or 
spread of common pathogens from normal flora and latent viral infections. 7 
 The clinical identification of infections can contribute to the diagnosis in more 
than 30% of the cases of FN and thus guide the treatment. However, a relevant portion 
(10-60%) of FN in patients is treated due to fever of unknown origin, without elucidating 
the pathogen.8 
 The purpose of this review is to identify, in the literature, randomized clinical 




 The question used to guide the research was: what is the most used therapy to treat 
FN in pediatric onco-hematological patients? 
This is a literature review based on PICO strategy. The population consisted of 
pediatric patients with solid or hematological tumors who developed FN and who needed 
treatment with antimicrobial or antifungal agents. They were randomized to studies that 
aimed to compare the effectiveness of each treatment and, with that, to define the best 
conduct for this population. 
The search was carried out in literature through combination of “Febrile 
Neutropenia”, “Pediatric” and “Therapeutics” descriptors using the Boolean operators 
(OR and AND) and limited to the English language. These criteria were defined after a 
search for articles was carried out in other databases, such as Scielo and LILACS, in 
Brazilian Portuguese, English and Spanish, not finding studies that fit the defined criteria, 
so it was decided to include only the articles found on PubMed.  
Articles published from 2009 to 2019, a randomized clinical trial comparing 
treatments for FN in pediatric onco-hematological patients (maximum age up to 18 years) 
were included. Review articles, guidelines, case reports, non-pediatric population (over 
18 years old), duplicate articles, which addressed FN prophylaxis or which did not address 
the comparison of treatments for FN were excluded. The search was limited to pediatric 
onco-hematological patients, as information on treatment and management of FN in this 




After selecting the articles by two reviewers screened using the keywords, the 
titles and abstracts were read, focusing on their methodology. The data of the selected 
articles were compiled and presented in a table, according to the objectives of this review. 
RESULTS AND DISCUSSION 
 The search in the database resulted in a total of 233 articles that met the descriptors 
used. Of these, 217 were excluded after reading the summary. A total of 16 articles were 
selected for detailed analysis. Nine articles were excluded because they did not address 
the comparison between treatments for FN in randomized controlled trials. Thus, seven 
articles presented information relevant to the research objective for this review, as 















Figure 1. Flowchart of articles selected for review. 
 
 Of the seven articles selected, five sought to compare antimicrobial regimens, an 
antifungal regimen and a treatment for viral infections.9-15 In clinical practice, most 
infections that affect patients with FN are caused by bacteria and because of this, studies 
mainly seek to define the best antimicrobial scheme (ATB) to be used in this clinical 
situation. Only one article used a different definition for FN, characterized by ANC of ≤ 
Studies found (n=233) 
Due to duplication (n=2) 
Due to not addressing FN 
treatment (n=213) 
Due to age (n=2) 
Articles selected for detailed 
analysis (n=16) 
Excluded because the objective 
was not to compare FN treatment 
(n=9) 




1000 cells/mm³, the others used the ESMO criterion.10 The most frequent ATB in the 
regimens was piperacillin/tazobactam (PIP/TAZ) and amoxacillin/clavulanate 
(AMOX/CLAV).9-13 Only two articles described the chemotherapeutic drugs used in the 
treatment of pediatric onco-hematological patients. 9,13 The most frequent neoplasm in 
the cases of FN in the articles assessed was acute lymphoid leukemia, with a high 
prevalence of other hematological neoplasms compared to solid tumors. Three articles 
described the FN classification criteria, but they were not the same criteria.10,13-14 There 
was evidence of infection in the seven articles.9-15 
 FN is a clinical condition originated by chemotherapy, which can make an 
individual susceptible to infections. Patients’ characteristics (age, neoplasia, treatment, 
type of infection, performance status) need to be considered when choosing the best 
therapy. 
 Bacterial infections are generally associated with FN in onco-hematological 
patients, and the identification of the pathogen causing the infection is important for 
choosing the appropriate ATB. The use of empirical PIP/TAZ in the management of 
patients with FN is explained by its spectrum of action, which includes the 
microorganisms most associated with FN in pediatric patients (Enterobacteriaceae (30%) 
and Coagulase-negative staphylococci (24%), and Pseudomonas aeruginosa (5%)).16,17 
 No statistically significant differences were found in clinical outcomes when 
compared to therapy with PIP/TAZ versus cefepime, drugs routinely used in bacterial 
infections in neutropenic patients. However, an increase in mortality was observed in the 
PIP/TAZ group, when patients have a previous history of treatment with etoposide, a 
chemotherapy used in several protocols for childhood and juvenile neoplasms. This 
reinforces the importance of knowing patients’ history and assessing the medications they 
use so that the choice of ATB is adequate, as this information may interfere with patients’ 
clinical evolution.9,18 
 The combination of PIP/TAZ with other ATBs can help to improve the clinical 
condition of patients with FN, however, it is essential to define the best association. One 
study found that sulbactam/ampicillin associated with aztreonam (62.5%) is equivalent to 
or higher than PIP/TAZ associated with ceftazidime, (57.1%), with fewer cases of new 





Caption: PIP/TAZ: Piperacillin-Tazobactam; CEF: Cefepime; ALL: Acute Lymphoid Leukemia; AML: Acute Myeloid Leukemia; CML: Chronic Myeloid Leukemia; NHL: 
Non-Hodking Lymphoma; HL: Hodking lymphoma; Arm A: without antifungal treatment; Arm B; Liposomal Amphotericin B; Arm C: Caspofungin; CT: Chemotherapy; G-
CSF: Granulocyte Colony-Stimulating Factor; FN: Febrile Neutropenia; OR: Oral route; IV: Intravenous; HSCT: Hematopoietic Stem Cell Transplantation; CAZ: Ceftazidime; 
SBT/ABPC: Sulbactam/Ampicillin; AZT: Aztreonam; AMK: Amikacin; CS: Cefoprazone + Sulbactam; OFL: Ofloxacin; AMOX/CLAV: Amoxicillin + Clavulanate; CEF: 
Ceftriaxone; GEM: Gentamicin 
  
Chart 1. Distribution of articles included in this literature review, according to the reference, type of study, study description, neoplasia, chemotherapy, therapy used, results 
and limitations, PubMed, 2009-2019. 
 
Reference Type of study Description of study Neoplasm Chemotherapy Therapy used Result Limitations 
Aamir, M., et al, 






Patients aged ≤18 years, 
receiving CT, who did not 
receive ATBs in 1 week. 
ALL (n=18), 
osteosarcoma (n=10), 
Ewing’s sarcoma (n=4), 
NHL (n=4), AML (n=4) 
Antibiotics (36), vinca 
alkaloids (26), folic acid 
analogs (22), steroids (18), 
alkylating agents (18), 
enzymes (18), 
epipodophyllotoxins (12), 
platinum complexes (10), 
analogues of pyrimidines (8) 
Group 1: PIP/TAZ 
100mg/Kg/dose 8h/8h 
IV; Group 2: CEF 
50mg/Kg/dose 8h/8h IV 
Success rate: Group 1: 75%; Group 2: 
80% There was no significant 
difference between the two groups 
(P=0.705). Mortality rate doubled in 
the PIP/TAZ group when patients used 
Etoposide. 
Small sample, schematics 
should be assessed in a 
larger sample. 
Gupta, A. et al, 





Patients aged between 2 and 
15 years, with low-risk FN, 
who did not need 
hospitalization. 





(n=17)*, Others (n=14)*. 
Number of episodes* 
Cis/adria: cisplatin, 
adriamycin (n=8); ECI: 
ifosfamide, carboplatin, 
etoposide (n=4); Ifos/adria: 
ifosfamide, adriamycin (n=4); 
Ifos/etop: ifosfamide, 
etoposide (n=21), VAC: 





others (n=6), indicated for 
ALL (n=41). 
Group 1: OFL OR 7.5 
mg/Kg 12/12h and 
AMOX/CLAV OR 12.5 
mg/Kg 8h/8h; Group 2: 
CEF EV 75mg/Kg and 
AMK IV 15mg/Kg IV 1 
time daily. 
Success rate: Group 1: 90.32%; Group 
2: 93,44%. No statistical difference 
(P=0.56).  
Parents checked the 
temperature. Although there 
is no statistical difference 
between the groups, due to 
convenience and fewer 
invasive procedures, the use 
of oral therapy could be 
highlighted. 








Patients aged ≤18 years, with 
CT-induced neutropenia or 
HSCT, persistent fever after 
96h even after ATB use. 
Patients were divided into low 
or high-risk groups, according 
to criteria. 
ALL (n=29), AML 
(n=32). CML (n=1), 
lymphoma (n=13), brain 
tumor (n=15), other solid 
tumors (n=19), severe 
aplastic anemia (n=1). 
Not described. Arm A: control group 
(low-risk patients 
without receiving 
antifungal); Arm B: 
3mg/Kg/day IV; Arm C 
50mg/m²/day, with an 
attack dose of 
70mg/m²/day. IV;  
Patients classified as high risk: Arm B: 
88%; Arm C: 83% (P=0.72). Patients 
classified as low risk: Arm A: 87.5%, 
Arm B: 80%, Arm C: 94.1% (P=0.41). 
The three experimental arms provided 
complete response (i.e., survival), 
disappearance of fever and no 
evidence of fungal infection. 
There was evidence of 
fungal infection in only 9 of 
the 110 patients. It would be 
important to have isolation 
of the fungus greater sample. 
One of the arms could be 
composed of antifungal 
slower spectrum of action, 
such as fluconazole, 
routinely used. 
 
Caption: PIP/TAZ: Piperacillin-Tazobactam; CEF: Cefepime; ALL: Acute Lymphoid Leukemia; AML: Acute Myeloid Leukemia; CML: Chronic Myeloid Leukemia; NHL: 
Non-Hodking Lymphoma; HL: Hodking lymphoma; Arm A: without antifungal treatment; Arm B; Liposomal Amphotericin B; Arm C: Caspofungin; CT: Chemotherapy; G-
CSF: Granulocyte Colony-Stimulating Factor; FN: Febrile Neutropenia; OR: Oral route; IV: Intravenous; HSCT: Hematopoietic Stem Cell Transplantation; CAZ: Ceftazidime; 
SBT/ABPC: Sulbactam/Ampicillin; AZT: Aztreonam; AMK: Amikacin; CS: Cefoprazone + Sulbactam; OFL: Ofloxacin; AMOX/CLAV: Amoxicillin + Clavulanate; CEF: 







et al, 2017, 





Patients aged 18 ≤ and FN 
were treated with 4th 
generation cephalosporins. 
After 48 hours, patients with a 
positive sample for respiratory 
virus and negative culture for 




recurrence (n=11), solid 
tumor (n=61). 
Not described. Group 1: Permanence of 
AtB until the end of the 
febrile episode; Group 
2: ATB withdrawal. 
 The median duration of ATBs was 7 
days (group 1) versus 3 days (group 2) 
(P=<0.0001), with similar frequency 
of uncomplicated resolution (97% 
versus 95%, respectively) (P=0.41) 
and a similar number of fever days (2 
versus 1), hospitalization days (6 
versus 6) and bacterial infections 
throughout the episode (2% versus 
1%). 
There were no deaths. 
It does not clearly 
demonstrate the outcome 
between the groups. They 
use as conclusion the 
incorporation of techniques 
to determine viral infections 
in the routine, not 
highlighting the result. This 
study could have highlighted 
the result that the 
withdrawal of ATB when it 
is not necessary, does not 
decrease the success of 
solving the problem, and 
may contribute to the 
reduction of microbial 
resistance. 
Cagol, A.R., et 








Patients aged 18 ≤, with 
neutropenia episode, classified 
as low risk for bacterial 
invasion, treated with CT. 
Osteosarcoma (n=10), 
primitive 
neuroecctodemic tumor of 
the central nervous system 
(n=7), T=Willm’s tumor 
(n=7), rhabdomyosarcoma 
(n=6), soft tissue sarcoma 
(n=7), leukemia (n=7), 
hepatoblastoma (n=2), 
neuroblastoma (n=6), 
lymphoma (n=1), gonadal 
tumor (n=1), Ewing’s 
sarcoma (n=2), 
retinoblastoma (n=2). 
Not described. Group A: Ciprofloxacin 
30mg/Kg/day 12h/12h 
OR + AMOX/CLAV 
30mg/Kg/day 8h/8h OR 
+ placebo IV. Group B: 
Cefepime 
150mg/Kg/day 8h/8h IV 
and placebo OR. 
Group A: ineffectiveness rate was 
51.2%, with an average length of 
hospitalization of 8 days. 
Group B: ineffectiveness rate was 
45.8%, with an average length of 
hospitalization of 7 days. No statistical 
difference (P= 0.77). Number of 
episodes in which patients remained 
with fever after 72h: Group A: 7 
episodes; Group B: 14 episodes. 
 
The way of classification of 
patients with FN was 
different from the other 
studies. It could have been 
highlighted the fact that 
there was no significant 
difference between the 
groups, saying that if 
patients had the OR 
preserved, it would be the 
preferred route for 
treatment, avoiding 
unnecessary punctures. 
Reference Type of study Description of the study Neoplasm Chemotherapy Therapy used Result Limitations 
 
Caption: PIP/TAZ: Piperacillin-Tazobactam; CEF: Cefepime; ALL: Acute Lymphoid Leukemia; AML: Acute Myeloid Leukemia; CML: Chronic Myeloid Leukemia; NHL: 
Non-Hodking Lymphoma; HL: Hodking lymphoma; Arm A: without antifungal treatment; Arm B; Liposomal Amphotericin B; Arm C: Caspofungin; CT: Chemotherapy; G-
CSF: Granulocyte Colony-Stimulating Factor; FN: Febrile Neutropenia; OR: Oral route; IV: Intravenous; HSCT: Hematopoietic Stem Cell Transplantation; CAZ: Ceftazidime; 
SBT/ABPC: Sulbactam/Ampicillin; AZT: Aztreonam; AMK: Amikacin; CS: Cefoprazone + Sulbactam; OFL: Ofloxacin; AMOX/CLAV: Amoxicillin + Clavulanate; CEF: 




Reference Type of study Description of the study Neoplasm Chemotherapy Therapy used Result Limitations 
Reference Type of study Description of the study Neoplasm Chemotherapy Therapy used Result Limitations 
Kobayashi, R. et 





Pediatric patients aged 17 ≤ 17 
years, with FN in CT or who 
received HSCT. 
ALL (n=46)*, AML 




(n=4)*, calf sac tumor 
(n=3)*, Ewing’s sarcoma 
(n=2)*, LH (n=2)*, NHL 
(n=2)*, 
rhabdomyosarcoma 
(n=2)*, Wilms’ tumor 
(n=1)*. 
Number of episodes* 
Not described. Group 1: PIP/TAZ 
125mg/Kg/day 6h/6h IV 
+ CAZ 100mg/Kg/day 
6h/6h IV; Group 2: 
SBT/ABPC 
150mg/Kg/day IV + 
AZT 150mg/Kg/day 
6h/6h IV.5 
Success rate Group 1: 57,1%; Group 
2: 62,5%. Success rate considered 
equivalent (P>0.05). Length of 
neutropenia, treatment, and days of 
fever were similar in both groups, but 
there were fewer new infections and 
deaths due to infection in Group 2. 
 In the “Patients and 
Methods” topic, it is 
described that the sample is 
composed of 54 patients, but 
in the description of the 
results, it is changed to 53. 
Neoplasms are not 
mentioned by number of 
patients, but by episodes of 
FN. There was evidence of 
infection in only 14 episodes 
in group 1 and 8 episodes in 






et al, 2013, 














Patients from 0-18 years with 
FN, diagnosed with lymphoma 
or other solid tumor, without 
antibiotic prophylaxis.  





germinoma (n=1), tumor 
atypical teratoid rhabdoid 




(n=1), Wilms’ tumor 
(n=1), rhabdoid tumor of 
the kidney (n=1), clear cell 













Success rate: Group 1: 47,5%; Group 
2: 52,7%. 
No statistical difference in length of 
neutropenia, fever and hospitalization 
(P=>0.05) 
From a total of 116 episodes 
of NDF, they needed 
treatment modification 
(adding other ATBs and/or 
antifungals) in 31 episodes in 
group 1 and 27 in group 2, 
characterizing half of 
episodes, which can interfere 
in the success rate, 





PIP/TAZ and amikacin compared to the association of cefoperazone/sulbactam and 
amikacin, found no statistical difference between the groups (47.5% versus 52.6%, 
respectively). The search for different combinations of ATB is essential, especially in 
cases of microbial resistance or non-response to PIP/TAZ, requiring the use of other 
effective alternatives, such as schemes with broad-spectrum ATB that are not routinely 
used.12 
In practice, the concern with the rapid evolution of the infection, makes the use of 
ATB often occur empirically. In this context, the use of PIP/TAZ for the empirical 
treatment of FN is of great value, as demonstrated in a study, in which the results found 
showed that the decrease in body temperature in patients occurred in 62.5% on the fourth 
day, 57.1% on the seventh day and 75.0% at the end of treatment, suggesting that the 
applicability of the empirical form of PIP/TAZ is satisfactory for the resolution of FN.19 
Comparing the use of oral ATB with intravenous ATB in patients with FN can be 
an effective alternative, especially for those who have a low risk of infection and with the 
opportunity to perform treatment at home. The use of oral ATB can facilitate treatment in 
pediatrics, allowing greater autonomy for family members and patients, decreasing the 
number of punctures, in addition to being also considered the alternative of hospital 
discharge, reducing the possibility of exposure to nosocomial infection and providing 
reduction of hospitalization costs.13,17,20–22 
 However, it is important to classify the severity of the risk of infection for this 
patient, considering several factors that directly affect the conduct to be taken. There is 
no internationally accepted risk stratification, requiring each hospital to choose a 
validated stratification and adapt to its reality. Risk score for children with FN was 
validated in a hospital in India and compared with other models already published. The 
authors concluded that this model demonstrated applicability, however, a multicenter 
study is needed to verify the possibility of employment in practice in developed countries, 
in which health conditions differ from those in development, such as malnutrition. 23-25  
 Despite the fact that most infections in FN patients are of microbial origin, other 
etiologic agents such as fungi and mycobacteria can also be the cause, especially in more 
severe and prolonged episodes of neutropenia, in a period longer than 10 days of 
hospitalization. 26 
Fungi can be considered responsible for 30-40% of infections after the fifth day 
of neutropenia, the most common being Candida albicans and Aspergillus, but there is 




effectiveness of two antifungals, caspofungin and amphotericin B liposomal in patients 
divided into low and high-risk groups. The results found, demonstrated that both 
treatments are effective for management of fungal infections in patients with FN. 
However, it is important to develop studies that compare broad-spectrum antifungals with 
those of minors, most used in routine.14,27  
 In addition to bacterial or fungal infections, viral infections, especially respiratory 
infections, appear as potential pathogens in this specific population. Viral respiratory 
infections can induce morbidity and mortality, being detected in more than 57% of FN 
episodes in children with cancer. 28,29 
 It is essential to determine the type of pathogen that causes the infection for the 
appropriate choice of therapy, since ATBs are ineffective in viral infections and their 
indiscriminate use can induce antimicrobial resistance. The suspension of ATB after 
confirming the results of negative cultures, does not interfere in the final outcome, with 
the resolution rates in both groups without significant difference (97% in the group with 
ATB and 95% in the group without ATB). 15 
 The use of adjuvant therapies to decrease patients’ neutropenia time can be 
considered a useful tool, such as the use of granulocyte growth stimulating factors (G-
CSF), adopted in the onco-hematological routine. Its use contributes to the increase of 
ANC and, with that, it decreases the time that patients would be susceptible to 
opportunistic infections, also reducing the time of use of ATB.30,31 
 The guidelines for initial management of FN in children and adolescents with 
cancer, published by the Brazilian Society of Pediatrics, indicate the initial empirical use 
of monotherapy with B-lactam antipseudomonal, fourth-generation cephalosporin or 
carbapenem.32 These indications corroborate the studies included in this review, in which 
most studies used PIP/TAZ and/or cefepime as ATB compared to other ATB. 
 Although the empirical use of PIP/TAZ is widespread in the treatment of FN in 
pediatric onco-hematological patients, it is necessary to consider the infectious focus and 
modify the therapy as necessary. For this, it can be considered that the stewardship 
program, a term used to describe an integrated strategy that seeks to reduce the irrational 
use of ATB, helps in choosing the best treatment. This program has acquired some 
objectives over the years, including cost reduction, optimization of therapeutic results and 
reduction of antimicrobial resistance, associated with tools that are characterized by the 
restrictions of ATB classes, rotation in the use of ATB, support in clinical decisions, 




 Recent systematic reviews and meta-analysis on stewardship differ in some 
points, however they converge in the fact that the application of this tool reduces the 
occurrence of nosocomial infections caused by drug-resistant bacteria. Moreover, it 
increases control and reduces the time of using ATB, without increasing the mortality 
rate, reducing hospital length of stay.35,36 
 Establishing protocols of the stewardship program in pediatric onco-
hematological patients with FN, can be a useful resource for decreasing microbial 
resistance and the unnecessary use of broad-spectrum ATB. As they are patients who 
often use protocols that cause severe myelosuppression, when they have neutropenia, they 
seek to protect themselves from serious infections, but that can often be treated simply, 
and in some cases, on an outpatient basis. 
 
CONCLUSION 
 Treatment with ATB was the most used, with PIP/TAZ being the most frequent 
in the regimens, followed by AMOX/CLAV. There was no statistically significant 
difference between treatment outcomes. However, length of stay, ANC, presence of fever 
and other clinical conditions must be taken into account when choosing the most 
appropriate ATB. Viral and fungal infections need to be considered to determine 
treatment with the correct class of drugs, and to avoid the irrational use of ATB. The 
establishment of standardized risk classification scores in pediatric onco-hematological 





1.  Instituto Nacional de Câncer José Alencar. Inca estimativa 2018[Internet]. Rio de 
Janeiro: INCA, 2017 [citado out 2019]. Available from: 
http://www1.inca.gov.br/estimativa/2018/estimativa-2018.pdf 
2.  Rasmy A, Amal A, Fotih, S. et al. Febrile Neutropenia in Cancer Patient: 
Epidemiology, Microbiology, Pathophysiology and Management. J Cancer Prev Curr Res 
.2016 Aug 23;5(3). 00165. http://dx.doi.org/10.15406/jcpcr.2016.05.00165 
3.  Stephanos K, Picard L. Pediatric Oncologic Emergencies. Emerg Med Clin North 
Am. 2018;36(3):527–35. http://dx.doi.org/10.1016/j.emc.2018.04.007 
4.  Silva SEM, da Silva IB. Epidemio. Perfil das urgências onco-hematológicas em 
crianças e adolescentes atendidos em um hospital público de referência. Enferm Bras. 
2017;16(5):293–302. http://dx.doi.org/10.1017/CBO9781107415324.004 
 5.  Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et 
al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 
2016;27(October 2008):v111–8. http://dx.doi.org/10.1093/annonc/mdw325 
 6.  Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin 
M, et al. Guideline for the management of fever and neutropenia in children with cancer 
and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 
2017;35(18):2082–94. http://dx.doi.org/10.1200/JCO.2016.71.7017 
 7.  Silva, D.; Andrea, M.L.M., Lins AGN. Emergências oncológicas. In: Tratado de 
pediatria. 4th ed. 2017. p. 1564–1470. 
8.  Kara Ö1, Zarakolu P, Aşçioğlu S, Etgül S, Uz B, Büyükaşik Y AM. Epidemiology 
and emerging resistance in bacterial bloodstream infections in patients with hematologic 
malignancies. Infect Dis (Auckl). 2015;47(10):686–93. 
http://dx.doi.org/10.3109/23744235.2015.10511053 
9.  Aamir M, Abrol P, Sharma D, Punia H. A clinical evaluation of efficacy and safety 
of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age 
group with febrile neutropenia in a tertiary care centre of north India. Trop Doct. 
2016;46(3):142–8. http://dx.doi.org/10.1177/0049475515617571 
 10.  Cagol ÂR, De Castro Junior CG, Martins MC, Machado AL, Ribeiro RC, 
Gregianin LJ, et al. Oral vs. intravenous empirical antimicrobial therapy in febrile 
neutropenic patients receiving childhood cancer chemotherapy. J Pediatr (Rio J). 
2009;85(6):531–5. http://dx.doi.org/10.2223/JPED.1956 
11.  Kobayashi R, Sato T, Nakajima M, Kaneda M, Iguchi A. Piperacillin/tazobactam 
plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for 
fever in severely neutropenic pediatric patients. J Pediatr Hematol Oncol. 
2009;31(4):270–3. http://dx.doi.org/10.1097/MPH.0b013e31819daf4a 
12.  Demirkaya M, Çelebi S, Sevinir B, Hacimustafaoglu M. Randomized comparison 
of piperacillin-tazobactam plus amikacin versus cefoperazone-sulbactam plus amikacin 
for management of febrile neutropenia in children with lymphoma and solid tumors. 
Pediatr Hematol Oncol. 2013;30(2):141–8. 
http://dx.doi.org/10.3109/08880018.2012.756565 
13.  Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized control 
trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone 
and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr 
Hematol Oncol. 2009;31(9):635–41. http://dx.doi.org/10.1097/MPH.0b013e3181acd8cd 
14.  Caselli D, Cesaro S, Ziino O, Ragusa P, Pontillo A, Pegoraro A, et al. A 
prospective, randomized study of empirical antifungal therapy for the treatment of 





15.  Santolaya ME, Alvarez AM, Acuña M, Avilés CL, Salgado C, Tordecilla J, et al. 
Efficacy and safety of withholding antimicrobial treatment in children with cancer, fever 
and neutropenia, with a demonstrated viral respiratory infection: a randomized clinical 
trial. Clin Microbiol Infect. 2017;23(3):173–8. 
http://dx.doi.org/10.1016/j.cmi.2016.11.001 
 16.  Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et 
al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and 
cancer patients. J Infect. 2014;68(4):321–31. http://dx.doi.org/10.1016/j.jinf.2013.12.006 
 17.  Santos, L., Torriani, M.S., Barros E. Medicamentos na prática da farmácia clínica. 
1ª ed. Porto Alegre: Artmed; 2013 
18.  Patel P, Lavoratore SR, Flank J, Kemp M, Vennettilli A, Vol H, et al. 
Chemotherapy-induced nausea and vomiting control in pediatric patients receiving 
ifosfamide plus etoposide : a prospective, observational study. 2019. 
http://dx.doi.org/10.1007/s00520-019-04903-0 
19.  Tamura K, Akiyama N, Kanda Y, Saito M. Efficacy and safety of 
tazobactam/piperacillin as an empirical treatment for the patients of adult and child with 
febrile neutropenia in Japan. J Infect Chemother. 2015;21(9):654–62. 
http://dx.doi.org/10.1016/j.jiac.2015.05.00920 
 20. Loeffen EAH, te Poele EM, Tissing WJE, Boezen HM, de Bont ESJM. Very early 
discharge versus early discharge versus non-early discharge in children with cancer and 
febrile neutropenia. Cochrane Database Syst Rev. 2016;2016(2). 
http://dx.doi.org/10.1002/14651858.CD008382.pub2 
 21.  Gil-Veloz M, Pacheco-Rosas DO, Solórzano-Santos F, Villasís-Keever MA, 
Betanzos-Cabrera Y, Miranda-Novales G. Early discharge of pediatric patients with 
cancer, fever, and neutropenia with low-risk of systemic infection. Bol Med Hosp Infant 
Mex. 2018;75(6):352–7. http://dx.doi.org/10.24875/BMHIM.18000015 
22.  Miedema KGE, Tissing WJE, Abbink FCH, Ball LM, Michiels EMC, Van Vliet 
MJ, et al. Risk-adapted approach for fever and neutropenia in paediatric cancer patients - 
A national multicentre study. Eur J Cancer. 2016;53:16–24. 
http://dx.doi.org/10.1016/j.ejca.2015.10.065 
23.  da Silva DB, Barreto JHS, Cordoba JC, et al. Diretrizes Para O manejo inicial da 
neutropenia febril, após quimioterapia, em crianças e adolescentes com câncer. Soc Bras 
Pediatr. 2018.Disponível em : < 
https://www.sbp.com.br/fileadmin/user_upload/Oncologia_-_20942d-
Diretrizes_manejo_inicial_neutropenia_febril_pos_quimio__003_.pdf>  
24.  Rivas-Ruiz R, Villasis-Keever M, Miranda-Novales G, Castelán-Martínez OD, 
Rivas-Contreras S. Outpatient treatment for people with cancer who develop a low-risk 
febrile neutropaenic event. Cochrane Database Syst Rev. 2019;2019(3). 
http://dx.doi.org/10.1002/14651858.CD009031.pub2 
 25.  Das A, Trehan A, Oberoi S, Bansal D. Validation of risk stratification for children 
with febrile neutropenia in a pediatric oncology unit in India. Pediatr Blood Cancer. 
2017;64(6):1–8. http://dx.doi.org/10.1002/pbc.26333 
 26.  Hagag AA, Hassan SM, Elgamasy MA, Afifi IK. Study of Common Bacterial and 
Fungal Pathogens in Children with Hematological Malignancies during Febrile 
Neutropenia: Single Center Egyptian Study. Infect Disord Drug Targets . 2016;16(1):54–
62. http://dx.doi.org/0.2174/1871526516666151230124333 
27.  Kumar J, Singh A, Seth R, Xess I, Jana M, Kabra SK. Prevalence and Predictors 
of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for 





 28.  Benites ECA, Cabrini DP, Silva ACB, Silva JC, Catalan DT, Berezin EN, et al. 
Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy. 
J Pediatr (Rio J). 2014;90(4):370–6. http://dx.doi.org/10.1016/j.jped.2014.01.006 
29.  Wong-Chew RM, Espinoza MA, Taboada B, Aponte FE, Arias-Ortiz MA, 
Monge-Martínez J, et al. Prevalence of respiratory virus in symptomatic children in 
private physician office settings in five communities of the state of Veracruz, Mexico. 
BMC Res Notes. 2015;8(1):1–8. http://dx.doi.org/10.1186/s13104-015-1239-0 
30.  Dwivedi P, Greis KD. Granulocyte colony-stimulating factor receptor signaling 
in severe congenital neutropenia, chronic neutrophilic leukemia, and related 
malignancies. Exp Hematol. 2017;46:9–20. 
http://dx.doi.org/10.1016/j.exphem.2016.10.008 
31.  Younis T, Rayson D, Jovanovic S, Skedgel C. Cost-effectiveness of febrile 
neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant 
chemotherapy in breast cancer: a systematic review. Breast Cancer Res Treat. 
2016;159(3):425–32. http://dx.doi.org/10.1007/s10549-016-3954-1 
 32.  Akova M. Antimicrobial Stewardship in Hematology Patients 1st ed. Vol. 2, 
Antimicrobial Stewardship. Elsevier Inc.; 2017. 205–217. 
http://dx.doi.org/10.1016/B978-0-12-810477-4.00017-9.33 
 33. Sociedade Brasileira de Pediatria. Diretrizes para o manejo inicial da neutropenia 
febril, após quimioterapia, em crianças e adolescentes com câncer. Departamento 
Científico de Oncologia. 2018; (2). 
34.  R Rice LB. Antimicrobial Stewardship and Antimicrobial Resistance. Med Clin 
North Am [Internet]. 2018;102(5):805–18. http://dx.doi.org/10.1016/j.mcna.2018.04.004 
35.  Davey P, Scott CL, Brown E, Charani E, Michie S, Ramsay CR, et al. 
Interventions to improve antibiotic prescribing practices for hospital inpatients (updated 
protocol). Cochrane Database Syst Rev. 2017;2017(2). 
http://dx.doi.org/10.1002/14651858.CD011236.pub2 
 36.  Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Systematic review 
and meta-analysis of clinical and economic outcomes from the implementation of 





Tatiane Bertella contributed to the conception, design, analysis and writing of the article;  
Siomara Regina Hahn contributed to the planning, design, review and final approval of 
the article. 
All authors have approved the final version to be published and are responsible for all 
aspects of the work, including ensuring its accuracy and integrity. 
 
